Theophylline Tablet, Extended Release
Product Images NDC 70771-1783

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Theophylline (NDC 70771-1783). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Theophylline Extended-release Tablets 300mg (86fdabb8 C881 4695 8127 59b26998e365 01)

Description: This text provides information about Theophylline Extended-Release Tablets containing 300 mg each. The package is child-resistant and should be stored between 20°C to 25°C (68°F to 77°F). It also includes instructions on dispensing and storing the medication safely. The tablets are manufactured by Zydus Lifesciences Ltd. in Ahmedabad, India. Users are advised to check the package for the usual dosage and prescribing information.*

FDA Label Image

Theophylline Extended-release Tablets 450 mg (86fdabb8 C881 4695 8127 59b26998e365 02)

This is information about Theophylline Extended-Release Tablets. Each tablet contains 450 mg of Theophylline. Dosage information is available in the package insert. The tablets are child-resistant and should be stored between 20°C to 25°C. The manufacturer is Zydus Lifesciences Ltd. from Ahmedabad, India.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.